IP Library Granted Patent US 7,442,717
Granted Patent B2
US 7,442,717 · App. 10/771,185 · Granted Oct 28, 2008

Substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnostic aid

Assignee: Sanofi-Aventis Deutschland GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,442,717
App. No.
10/771,185
Granted
Oct 28, 2008
Kind
B2
Abstract

Novel substituted 2-aminoimidazoles of formula I, process for their preparation, their use as medicament or diagnostic aid, and medicament containing them. The compounds of this type are useful in the prevention or treatment of various disorders and can be employed inter alia for renal disorders such as acute or chronic renal failure, for disorders of biliary function, for respiratory disorders such as snoring or sleep apneas or for stroke

Claims (26)

1. A compound of formula I, or a pharmaceutically acceptable salt or trifluoroacetic acid salt of said compound:

where:

R1 and R2 together with the two carbon atoms to which they are bonded, form a five-, six-, seven- or eight-membered carbon ring comprising one or two double bonds, said ring being substituted by 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 fluorine atoms and further substituted by 0, 1, or 2 radicals selected from the group consisting of OH, NR9R10, alkyl with 1, 2, 3 or 4 carbon atoms, CN, CF 3 and alkoxy with 1, 2, 3 or 4 carbon atoms, wherein R9 and R10 are independently H or alkyl with 1, 2, 3 or 4 carbon atoms; or,

R3, R4, R5, R6 and R7 are independently selected from the group consisting of hydrogen, F, Cl, Br, I, alkyl with 1, 2, 3 or 4 carbon atoms and substituted by 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9 fluorine atoms, and alkoxy with 1, 2, 3 or 4 carbon atoms and substituted by 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9 fluorine atoms, provided that R3 and R7 are not both simultaneously hydrogen;

R8 is selected from the group consisting of H, alkyl with 1, 2, 3 or 4 carbon atoms and substituted by 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9 fluorine atoms, and cycloalkyl with 3, 4 or 5 carbon atoms and substituted by 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9 fluorine atoms.

2. The compound or salt of claim 1 , wherein:

R1 and R2, together with the two carbon atoms to which they are bonded, form a five-, six-, seven or eight-membered carbon ring comprising one or two double bonds, said ring being substituted by 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 fluorine atoms and further substituted by 0, 1, or 2 radicals selected from the group consisting of CH 3 and OCH 3 ;

R3, R4, R5, R6 and R7 are independently selected from the group consisting of hydrogen, F, Cl, Br, alkyl with 1, 2, 3 or 4 carbon atoms and substituted by 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9 fluorine atoms, and alkoxy with 1, 2, 3 or 4 carbon atoms and substituted by 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9 fluorine atoms, provided that R3 and R7 are not both simultaneously hydrogen.

3. The compound or salt of claim 2 , wherein:

R1 and R2, together with the two carbon atoms to which they are bonded, form a five-, six- or seven-membered carbon ring comprising a double bond,

R3 and R7 are independently selected from the group consisting of F, Cl, Br and alkyl has 1, 2, 3 or 4 carbon atoms and is substituted by 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9 fluorine atoms;

R4, R5 and R6 are H;

R8 is H or alkyl with 1, 2, 3 or 4 carbon atoms and substituted by 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9 fluorine atoms.

4. The compound or salt of claim 3 , which is selected from the group consisting of:

(2,6-dichlorophenyl)(4,5,6,7-tetrahydro-1H-benzoimidazol-2-yl)amine,

(2,6-dichlorophenyl)methyl(4,5,6,7-tetrahydro-1H-benzoimidazol-2-yl)amine, a pharmaceutically acceptable salt or trifluoroacetic acid salt of (2,6-dichlorophenyl) (4,5,6,7-tetrahydro-1H-benzoimidazol-2-yl)amine, and a pharmaceutically acceptable salt or trifluoroacetic acid salt of (2,6- dichlorophenyl)methyl(4,5,6,7-tetrahydro-1H-benzoimidazol-2-yl)amine.

5. The compound or a salt of claim 1 , wherein R3, R4, R5, R6 and R7 are independently selected from the group consisting of hydrogen, F, Cl, Br, and alkyl with 1, 2, 3 or 4 carbon atoms and substituted by 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9 fluorine atoms, provided that R3 and R7 are not both simultaneously hydrogen.

6. The compound or a salt of claim 5 , wherein:

R3 and R7 are independently selected from the group consisting of F, Cl, Br and alkyl with 1, 2, 3 or 4 carbon atoms and substituted by 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9 fluorine atoms;

R4, R5 and R6 are hydrogen;

R8 is either H or alkyl which has 1, 2, 3 or 4 carbon atoms and is substituted by 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9 fluorine atoms.

7. A method of manufacturing a drug by incorporating a compound or a salt of claim 1 , alone or in combination with one or more other drugs or active ingredients, in a pharmaceutically acceptable formulation for the treatment or prophylaxis of disorders of respiratory drive and/or of sleep-related respiratory disorders and sleep apneas.

8. The method of claim 7 , wherein said drug is for the treatment or prophylaxis of snoring.

9. The method of claim 7 , wherein said drug is for the treatment or prophylaxis of acute and chronic renal disorders, of acute renal failure or of chronic renal failure.

10. The method of claim 7 , wherein said drug is for the treatment or prophylaxis of disorders of intestinal function.

11. A pharmaceutical composition for human, veterinary or phytoprotective use comprising an effective amount of one or more compounds or salts of claim 1 .

Assignments (4)
CHANGE OF NAME Recorded Sep 9, 2008
From: AVENTIS PHARMA DEUTSCHLAND GMBH
To: SANOFI-AVENTIS DEUTSCHLAND GMBH
Reel/Frame 021501/0175 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2008
From: HEINELT, UWE; LANG, HANS-JOCHEN; HOFMEISTER, ARMIN; WIRTH, KLAUS; JANSEN, HANS-WILLI
To: AVENTIS PHARMA DEUTSCHLAND GMBH
Reel/Frame 021474/0515 →
CHANGE OF NAME Recorded Nov 18, 2005
From: AVENTIS PHARMA DEUTSCHLAND GMBH
To: SANOFI-AVENTIS DEUTSCHLAND GMBH
Reel/Frame 016793/0789 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2004
From: HEINELT, DR. UWE; LANG, DR. HANS-JOCHEN; HOFMEISTER, DR. ARMIN; WIRTH, DR. KLAUS; JANSEN, DR. HANS-WILLI
To: AVENTIS PHARMA DEUTSCHLAND GMBH
Reel/Frame 015124/0734 →
Priority Claims (1)
DE 103 04 374 · Feb 4, 2003 · national
Continuity (2)
Provisional Application 6047757000 · Jun 11, 2003
Related Publication 20040259927A1 · Dec 23, 2004